MeTA Process and Progress in Jordan

Rania Bader MeTA Consultant MeTA Process and Progress in Jordan MeTA 10/06/09

Jordan’s Fact Sheet
Population: 5.8 million
Health expenditure: 10.4 % of GDP
(30% of this spent on medicines)
Total Medicine Expenditure $ 338 Million
Public Medicine Expenditure $ 112.6 Million
25% Medicine expenditure (public sector)
75 % Medicine expenditure (private sector)
Local medicines manufacturers: 16
Medicines expenditure growth 17% per
annum compared to GDP growth of 3.3%
10/06/09 MeTA

What is MeTA?
MeTA brings together at the international and national levels, a diverse group of people working in the pharmaceutical sector through a ( multi-stakeholders approach ) to find ways to improve/increase transparency and accountability in selection, regulation, procurement, distribution and use of medicines in countries
MeTA partners are the UK Department for International Development ( DFID ) , the WHO and the World Bank (WB)
10/06/09 MeTA

Agenda
A. MeTA Process in Jordan
B. MeTA Progress in Jordan ( achievements so far)
C. Monitoring and Evaluation
D. Challenges
E. Key Successes
F. Getting more information
10/06/09 MeTA

MeTA Process in Jordan:
It started with scoping visits
Looked into reasons for Jordan to be one of the MeTA pilot Countries
Proposal was sent to the Government
The Government approved
Formed the MeTA Council / stakeholder
Drafting Jordan’s Workplan
MOU signed
10/06/09 MeTA

MeTA in Jordan
10/06/09 MeTA

The Minister of Health sent an official letter to MOPIC approving on having the High Health Council (HHC) hosting the MeTA Secretariat
10/06/09 MeTA

Jordan’s MeTA Council held its first meeting at the HHC in August 2008 after the MeTA council was formed and endorsed by the MOH, the council representation is from the Government, private sector, civil society organizations, professional organizations, and the academia. In addition non- voting representatives from the World Bank (WB), the World Health Organization (WHO) and Health Action international (HAI), with the presence of the MeTA national consultant in Jordan
10/06/09 MeTA

T he Council serves as the highest policy making and consultative body
The council elected his chairperson Dr Taher AbuElSamen and also nominated him to participate as Jordan’s representative on the MeTA International Advisory Group (MIAG) in London every year
10/06/09 MeTA

The MeTA Council drafted the internal rules and formed Three Committees then developed activities for the areas of work that they chose and included them in the Jordan MeTA workplan
Jordan MeTA workplan has been sent officially to the MMB on the 9 th of February 2009 for approval, and it was approved after 7 working days, MOU was signed accordingly
10/06/09 MeTA

The three committees that have been formed out of the MeTA Council are:
1- Evidence Based Decision Making for the RDL Committee
2- Encouraging Best Practice and Promote Rational Drug Use Committee
3- Civil Society organizations Building Capacity Committee
10/06/09 MeTA

MeTA Progress in Jordan
Supply Chain Mapping
Private Sector Mapping
CSO Mapping
NICE Training on Using Health Technology Assessment to inform decision-making in healthcare
MeTA Chair has Participated in the MIAG meeting
Held an important session on medicines and transparency at the WHA
10/06/09 MeTA

WHA 62 Geneva 2009
MeTA Jordan held an important session on medicines and transparency and Good Governance at the WHA, Geneva, on19th May. Over 80 participants from the WHA attended with representatives from over 20 different countries including Iraq, Libia,Ghana, Cameroon, Peru, Argentina, India, and Bangladesh
Members of the MeTA Jordan Council presented the work they have done so far in setting up a multi-stakeholder group comprising representatives from Government, the pharmaceutical industry, and civil society organizations
10/06/09 MeTA

Monitoring and Evaluation
Monthly progress reports of three working committees and MeTA Jordan Secretariat
Quarterly reports by MeTA Council to International MeTA Secretariat Reports will be published on national & international MeTA websites
Financial reporting by national MeTA Secretariat
External monitor from another MeTA pilot country on annual and also the CSO Alliance could be involved in the monitoring and evaluation process
10/06/09 MeTA

Challenges
Assuring commitment & engagement of ALL stakeholders
Clarity and understanding of MeTA’s objectives to Jordan’s MeTA Council stakeholders at ALL levels of their organisations
Lack of good quality information and data
Civil Society are in early stages of development
How to make the MeTA approach SUSTAINABLE
The concept behind MeTA processes to be country-led, that in a way caused the process in Jordan to be slower
10/06/09 MeTA

Key Successes
The full support from the Jordanian government, MOH and MOPIC
The full support from the international MeTA Secretariat
WHO Jordan Country Representative was very supportive
10/06/09 MeTA

Key Successes
DFID, WHO/HQ, WB and WHO/EMRO regional office were very supportive
Cooperation between all stakeholders including the private sector and the Council members from all sectors were highly committed to moving the MeTA process forward
10/06/09 MeTA

References for getting more Information:
http://www.medicinestransparency.org/meta-countries/jordan/
http://www.haiweb.org/medicineprices/surveys/200405JO/survey_report.pdf
http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-Briefing-note.pdf
http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-MeTA-Country-Jordan.pdf
http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHO-HAI-summary-report.pdf
http://www.medicinestransparency.org/news-events/article/view/information-about-medicines-where-to-start/80/
10/06/09 MeTA

Thank you!
Rania Bader
Email: raniasb2002@yahoo.com
Mobile number +962 79 5691921
MeTA: www.MedicinesTransparency.org
10/06/09 MeTA

MeTA Process and Progress in Jordan

by MeTApresents on Jun 08, 2009

Accessibility

Categories

Tags

Upload Details

Usage Rights

Statistics

MeTA Process and Progress in Jordan — Presentation Transcript